INDICATIONS

Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate® is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.


Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.

... Read More 
Nplate (romiplostim) out-of-pocket (OOP) costs
81% of Nplate® claims have $0 out-of-pocket costs for the patient1,*

*Among the 19% of Nplate® claims where patients had out-of-pocket (OOP) costs, most claims (72%) had an OOP cost of less than $400. Data based on Symphony Health Solutions claims data. 24,199 Nplate® claims were identified between 1/1/2019 - 12/31/2019 for all payors, including commercial and government.1

See How We Can Help Your Patients

Amgen Assist 360™ and Nplate® Navigator are here to offer the tools, information, and support for Amgen products that make a difference for you and your patients.

Learn more below, or contact Amgen Assist 360™ at 1‑888‑4ASSIST1‑888‑4ASSIST or visit AmgenAssist360.com for more information.

Patient access and reimbursement
Patient support

Amgen Assist 360™:
Introducing support, simplified

Amgen Reimbursement Specialists

  • Connect with an Amgen Reimbursement Counselor or schedule a visit with a Field Reimbursement Specialist
Patient Resource Guide
  • Find co-pay and reimbursement resources for patients with different kinds of insurance or no insurance at all
Benefit Verification
  • Submit, store, and retrieve benefit verifications for all your patients currently on an Amgen product

To learn more, please visit www.AmgenAssist360.com.

The Amgen FIRST STEP™ Prepaid Mastercard® is issued by Comerica Bank pursuant to license by Mastercard® International Incorporated. No cash or ATM access. Mastercard® is a registered trademark of Mastercard® International Incorporated. This card can be used only to cover the co-payment for eligible prescriptions covered under the program at participating merchant locations where Debit Mastercard® is accepted.

The Amgen FIRST STEP™ program

Who it may help

  • Eligible commercially insured patients

The Amgen FIRST STEP program can help your eligible commercially insured patients cover their out-of-pocket (OOP) prescription costs, including deductible, co-insurance, and co-payment.

  • $0 OOP for first dose
  • $5 OOP for subsequent doses, up to the brand benefit maximum
  • No income eligibility requirement

Learn More. Visit AMGENFIRSTSTEP.COM or call1-888-65-STEP11-888-65-STEP1 (1-888-657-83711-888-657-8371) Monday-Friday, 9 AM to 8 PM ET.

See AmgenFirstStep.com for terms and conditions.

Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.

Referrals to the Amgen Safety Net Foundation

  • The Amgen Safety Net Foundation provides Amgen products at no cost to qualifying patients.
  • Patients may qualify if they have no or limited drug coverage and meet income eligibility requirements.
  • Patient must be a US resident to qualify.

For more information, please contact the Amgen Safety Net Foundation at 1-888-762-64361-888-762-6436 or visit AmgenSafetyNetFoundation.com.

Learn about Nplate® Navigator Patient Support

Nplate® Navigator patient support program

Nplate® Navigator may help:

  • Answer questions about immune thrombocytopenia (ITP) and Nplate® by allowing your patients to speak with a nurse*
  • Provide information about finding resources that may be able to help your patients afford their medication
  • Identify a list of local ITP specialists while patients are traveling or relocating domestically
  • Keep patients informed with educational emails and direct mailings

*The Nplate® Navigator program and its nurses are not intended to provide medical advice, diagnose health problems, or take the place of speaking with a healthcare professional about a patient’s condition, treatment, or medication.

Patients can call Nplate® Navigator toll-free at 1‑855‑7Nplate1‑855‑7Nplate (1‑855‑767‑52831‑855‑767‑5283) Monday through Friday, 9:00 AM–9:00 PM ET or sign up online.

Learn about patient access and reimbursement

Important Safety Information

Risk of Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia

  • In Nplate® (romiplostim) clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.
  • Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than ITP.

Thrombotic/Thromboembolic Complications

  • Thrombotic/thromboembolic complications may result from increases in platelet counts with Nplate® use. Portal vein thrombosis has been reported in patients with chronic liver disease receiving Nplate®.
  • To minimize the risk for thrombotic/thromboembolic complications, do not use Nplate® in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain a platelet count of ≥ 50 x 109/L.

Loss of Response to Nplate®

  • Hyporesponsiveness or failure to maintain a platelet response with Nplate® should prompt a search for causative factors, including neutralizing antibodies to Nplate®.
  • To detect antibody formation, submit blood samples to Amgen (1‑800‑772‑64361‑800‑772‑6436). Amgen will assay these samples for antibodies to Nplate® and thrombopoietin (TPO).
  • Discontinue Nplate® if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks at the highest weekly dose of 10 mcg/kg.

Adverse Reactions

Adult ITP
  • In the placebo-controlled trials of adult ITP patients, headache was the most commonly reported adverse drug reaction, occurring in 35% of patients receiving Nplate® and 32% of patients receiving placebo. Adverse drug reactions in adults with a ≥ 5% higher patient incidence in Nplate® versus placebo were Arthralgia (26%, 20%), Dizziness (17%, 0%), Insomnia (16%, 7%), Myalgia (14%, 2%), Pain in Extremity (13%, 5%), Abdominal Pain (11%, 0%), Shoulder Pain (8%, 0%), Dyspepsia (7%, 0%), and Paresthesia (6%, 0%).
  • The safety profile of Nplate® was similar across patients, regardless of ITP duration. The following adverse reactions (at least 5% incidence and at least 5% more frequent with Nplate® compared with placebo or standard of care) occurred in Nplate® patients with ITP duration up to 12 months: bronchitis, sinusitis, vomiting, arthralgia, myalgia, headache, dizziness, diarrhea, upper respiratory tract infection, cough, nausea and oropharyngeal pain. The adverse reaction of thrombocytosis occurred with an incidence of 2% in adults with ITP duration up to 12 months.
Pediatric ITP
  • The most common adverse reactions experienced by ≥ 5% of patients receiving Nplate® with ≥ 5% higher incidence in the Nplate® arm across the two placebo-controlled trials were contusion (41%), upper respiratory tract infection (31%), oropharyngeal pain (25%), pyrexia (24%), diarrhea (20%), rash (15%), and upper abdominal pain (14%).
  • In pediatric patients of age ≥ 1 year receiving Nplate® for ITP, adverse reactions with an incidence of ≥ 25% in the two randomized trials were: contusion (41%), upper respiratory tract infection (31%), and oropharyngeal pain (25%).

Nplate® administration may increase the risk for development or progression of reticulin fiber formation within the bone marrow. This formation may improve upon discontinuation of Nplate®. In a clinical trial, one patient with ITP and hemolytic anemia developed marrow fibrosis with collagen during Nplate® therapy.

INDICATIONS

Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate® is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.

Please see full Prescribing Information and Medication Guide.

Reference: 1. Data on file, Amgen; Patient OOP; 2019.

Back To Top

You are now leaving NplateHCP.com.

Please be aware that sponsors of this site are not responsible for content on the site you are about to enter.